tradingkey.logo

Twist Bioscience Corp

TWST
33.050USD
-0.530-1.58%
收盤 12/26, 16:00美東報價延遲15分鐘
2.00B總市值
虧損本益比TTM

Twist Bioscience Corp

33.050
-0.530-1.58%

關於 Twist Bioscience Corp 公司

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.

Twist Bioscience Corp簡介

公司代碼TWST
公司名稱Twist Bioscience Corp
上市日期Oct 31, 2018
CEOLeproust (Emily M)
員工數量979
證券類型Ordinary Share
年結日Oct 31
公司地址681 Gateway Blvd.
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94080
電話18007190671
網址https://www.twistbioscience.com/
公司代碼TWST
上市日期Oct 31, 2018
CEOLeproust (Emily M)

Twist Bioscience Corp公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
571.81K
-0.39%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
208.77K
+44.42%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
90.42K
-0.44%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
86.38K
-1.01%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
47.19K
+205.88%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
15.81K
+39.44%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
5.55K
-55.92%
Mr. Robert Werner
Mr. Robert Werner
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
571.81K
-0.39%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
208.77K
+44.42%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
90.42K
-0.44%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
86.38K
-1.01%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
47.19K
+205.88%

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
NGS tools
55.28M
57.55%
Synthetic genes
27.68M
28.82%
Antibody discovery
5.61M
5.84%
Oligo pools
5.42M
5.65%
DNA libraries
2.06M
2.14%
地區USD
名稱
營收
佔比
Americas
59.39M
61.82%
EMEA
30.74M
32.00%
APAC
5.93M
6.17%
業務
地區
業務USD
名稱
營收
佔比
NGS tools
55.28M
57.55%
Synthetic genes
27.68M
28.82%
Antibody discovery
5.61M
5.84%
Oligo pools
5.42M
5.65%
DNA libraries
2.06M
2.14%

股東統計

更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
ARK Investment Management LLC
11.00%
Artisan Partners Limited Partnership
10.48%
The Vanguard Group, Inc.
9.41%
BlackRock Institutional Trust Company, N.A.
7.87%
William Blair Investment Management, LLC
6.77%
其他
54.46%
持股股東
持股股東
佔比
ARK Investment Management LLC
11.00%
Artisan Partners Limited Partnership
10.48%
The Vanguard Group, Inc.
9.41%
BlackRock Institutional Trust Company, N.A.
7.87%
William Blair Investment Management, LLC
6.77%
其他
54.46%
股東類型
持股股東
佔比
Investment Advisor
66.18%
Investment Advisor/Hedge Fund
36.08%
Hedge Fund
9.93%
Research Firm
5.45%
Individual Investor
2.69%
Pension Fund
1.58%
Bank and Trust
0.55%
Family Office
0.17%
Insurance Company
0.07%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
566
71.88M
119.09%
+752.75K
2025Q2
575
70.44M
116.72%
-302.44K
2025Q1
585
70.23M
117.22%
-1.63M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
2023Q3
560
68.09M
118.66%
-11.36M
2023Q2
577
69.42M
121.49%
-5.07M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
ARK Investment Management LLC
6.40M
10.6%
+158.85K
+2.54%
Jun 30, 2025
Artisan Partners Limited Partnership
6.41M
10.62%
+1.35M
+26.67%
Sep 30, 2025
The Vanguard Group, Inc.
5.82M
9.64%
-36.15K
-0.62%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.86M
8.05%
+226.25K
+4.89%
Jun 30, 2025
William Blair Investment Management, LLC
3.91M
6.47%
+99.74K
+2.62%
Jun 30, 2025
EdgePoint Investment Group Inc.
2.39M
3.95%
+1.27M
+114.33%
Jun 30, 2025
State Street Investment Management (US)
2.50M
4.14%
-192.68K
-7.15%
Jun 30, 2025
Amova Asset Management Co., Ltd.
2.30M
3.81%
-116.36K
-4.82%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
ARK Genomic Revolution ETF
6.24%
iShares Genomics Immunology and Healthcare ETF
3.92%
Global X Genomics & Biotechnology ETF
2.09%
ROBO Global Healthcare Technology & Innovation ETF
2%
WisdomTree BioRevolution Fund
1.79%
ARK Innovation ETF
1.47%
Franklin Genomic Advancements ETF
1.17%
State Street SPDR S&P Biotech ETF
0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.66%
Direxion Daily S&P Biotech Bull 3X Shares
0.56%
查看更多
ARK Genomic Revolution ETF
佔比6.24%
iShares Genomics Immunology and Healthcare ETF
佔比3.92%
Global X Genomics & Biotechnology ETF
佔比2.09%
ROBO Global Healthcare Technology & Innovation ETF
佔比2%
WisdomTree BioRevolution Fund
佔比1.79%
ARK Innovation ETF
佔比1.47%
Franklin Genomic Advancements ETF
佔比1.17%
State Street SPDR S&P Biotech ETF
佔比0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
佔比0.66%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.56%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Twist Bioscience Corp的前五大股東是誰?

Twist Bioscience Corp的前五大股東如下:
ARK Investment Management LLC
持有股份:6.40M
佔總股份比例:10.60%。
Artisan Partners Limited Partnership
持有股份:6.41M
佔總股份比例:10.62%。
The Vanguard Group, Inc.
持有股份:5.82M
佔總股份比例:9.64%。
BlackRock Institutional Trust Company, N.A.
持有股份:4.86M
佔總股份比例:8.05%。
William Blair Investment Management, LLC
持有股份:3.91M
佔總股份比例:6.47%。

Twist Bioscience Corp的前三大股東類型是什麼?

Twist Bioscience Corp 的前三大股東類型分別是:
ARK Investment Management LLC
Artisan Partners Limited Partnership
The Vanguard Group, Inc.

有多少機構持有Twist Bioscience Corp(TWST)的股份?

截至2025Q3,共有566家機構持有Twist Bioscience Corp的股份,合計持有的股份價值約為71.88M,占公司總股份的119.09% 。與2025Q2相比,機構持股有所增加,增幅為2.37%。

哪個業務部門對Twist Bioscience Corp的收入貢獻最大?

在FY2025Q3,NGS tools業務部門對Twist Bioscience Corp的收入貢獻最大,創收55.28M,占總收入的57.55% 。
KeyAI